✦ New CED Clinical Relevance#72Notable Clinical InterestEmerging findings or policy developments worth monitoring closely. SafetyResearchMental HealthPediatrics Why This MattersCannabinoid hyperemesis syndrome and prenatal cannabis exposure represent clinically significant adverse outcomes that warrant...
Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know
WHY IT MATTERS: Patients and clinicians hoping for a targeted pharmacological tool to manage THC overconsumption or cannabis use disorder may face longer timelines before any such option becomes available. CLINICAL OVERVIEW: AEF0117 is a first-in-class CB1 receptor signaling inhibitor developed by Aelis Farma, designed to selectively block certain downstream effects of THC without fully antagonizing the receptor, representing a novel pharmacological approach to cannabis use disorder and THC-related adverse effects. The withdrawal of a THC interaction trial is a meaningful setback because interaction studies are critical for characterizing how AEF0117 behaves in the presence of active THC, which is the precise clinical scenario the drug is meant to address.
DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research Backed by NFL … – StreetInsider
WHY IT MATTERS: If thin-film CBD delivery is confirmed to offer superior and more consistent bioavailability compared to traditional oral products, patients may need to recalibrate their doses when switching formats to avoid unintended underdosing or overdosing. CLINICAL OVERVIEW: Sublingual and buccal thin-film delivery systems represent a meaningful departure from conventional oral cannabinoid formats because they bypass first-pass hepatic metabolism, potentially improving both the speed of onset and the consistency of systemic absorption. CBD delivered through mucoadhesive strip technology may achieve higher bioavailability compared to standard oil-based or capsule formulations, which are notoriously variable due to differences in fed versus fasted states and individual digestive physiology.
Cannabis use, anxiety and depression are all on the rise in Canada: study – CTV News
WHY IT MATTERS: Patients using cannabis to manage anxiety or depression should be aware that without proper medical guidance on strain selection, THC-to-CBD ratios, and dosing, cannabis may be worsening the very symptoms they are trying to treat. CLINICAL OVERVIEW: Research from Canada is highlighting a parallel rise in cannabis use alongside increasing rates of anxiety and depression, raising important questions about the direction of causality and the role cannabis may be playing in mental health outcomes. The relationship between cannabis and mood disorders is complex, as individuals may be turning to cannabis to self-manage psychological distress while the substance itself, particularly high-THC products, can worsen anxiety and depressive symptoms over time.
Marijuana Use & Dangers for Adolescents & Young Adults
WHY IT MATTERS: Parents, school counselors, and young people themselves should understand that regular cannabis use during adolescence is not a benign habit but a potential accelerant for mental health problems that may require professional intervention. CLINICAL OVERVIEW: Adolescents and young adults represent a particularly vulnerable population when it comes to cannabis use, largely because the brain continues developing well into the mid-twenties, making it highly susceptible to the neurological effects of THC during this window. When cannabis use disorder co-occurs with underlying mental health conditions such as anxiety, depression, or early psychotic spectrum disorders, the clinical picture becomes substantially more complex and harder to treat.
Screaming, vomiting, and daily weed: The rise of ‘scromiting’ among chronic cannabis users
WHY IT MATTERS: If you use cannabis daily and experience recurring episodes of severe vomiting that hot showers seem to relieve, you should discuss cannabinoid hyperemesis syndrome with your physician before your next emergency room visit. CLINICAL OVERVIEW: Cannabinoid hyperemesis syndrome is a paradoxical condition in which heavy, long-term cannabis use causes cyclical episodes of severe nausea, vomiting, and abdominal pain, often relieved temporarily by hot showers or baths. The syndrome is thought to involve dysregulation of cannabinoid receptors in the gut and hypothalamus, particularly with chronic high-potency THC exposure, though the precise mechanism remains under active investigation.
The Office Is Issuing A Recall On Multiple Adult-Use Cannabis Products Tested By Keystone …
WHY IT MATTERS: Patients and adult consumers purchasing cannabis from licensed New York dispensaries should check current recall lists and verify with their dispensary that any products they have recently purchased or plan to purchase have not been flagged for removal. CLINICAL OVERVIEW: Product recalls in regulated cannabis markets typically arise when testing laboratories identify contaminants such as pesticides, heavy metals, microbial agents, or inaccurate potency labeling that fall outside state-mandated safety thresholds. When a testing facility’s results are called into question or when products are found to be non-compliant, state regulators are obligated to pull those items from dispensary shelves to protect consumers.
OCM issues precautionary recall for select cannabis products tested by Keystone Lab – CBS 6 Albany
WHY IT MATTERS: Patients relying on tested and labeled cannabis products from New York dispensaries should check the OCM recall list to confirm their specific products are safe to use and return any flagged items to their point of purchase. CLINICAL OVERVIEW: Regulatory bodies like the New York State Office of Cannabis Management have the authority to issue precautionary recalls when questions arise about the accuracy or integrity of third-party laboratory testing, which serves as the primary safety checkpoint between cultivators and consumers. Cannabis testing laboratories are responsible for verifying potency, pesticide levels, heavy metals, residual solvents, and microbial contamination, and any uncertainty in those results can expose patients and consumers to unquantified risks.
Does Weed Make You Harder or Easier to Manipulate? – Herb
WHY IT MATTERS: Patients who use cannabis recreationally or medicinally should understand that high-dose THC can temporarily impair judgment and increase vulnerability to social influence, particularly in unfamiliar settings or with strangers. CLINICAL OVERVIEW: Cannabis influences judgment and decision-making through its effects on the prefrontal cortex, where THC disrupts the normal signaling of the endocannabinoid system and impairs executive function, working memory, and risk assessment. These cognitive effects are dose-dependent and highly variable based on individual tolerance, cannabinoid ratios, and consumption patterns, meaning that susceptibility to poor judgment or social manipulation is not uniform across all users.
Rare Cannabinoid Company Expands Mood Collection with New THC-Free CBC Gummies …
WHY IT MATTERS: Patients exploring THC-free options for mood support should know that CBC products are now commercially available, but the clinical evidence base is still largely preclinical and has not yet established clear dosing guidelines or confirmed efficacy in human trials. CLINICAL OVERVIEW: Cannabichromene (CBC) is a non-intoxicating phytocannabinoid that interacts with the endocannabinoid system through mechanisms distinct from CBD and THC, including potential influence on anandamide availability rather than direct binding at CB1 or CB2 receptors. Early preclinical research points toward possible mood-related and anti-inflammatory effects, though human clinical trial data remains limited.